title: Cell surface expression of CD25, CD54, and CD95 on B- and T-cells in chronic lymphocytic leukaemia in relation to trisomy 12, atypical morphology and clinical course.
abstract: BACKGROUND
  Surface antigen expression can be used to define subgroups of patients with different clinical courses in chronic lymphocytic leukaemia of the B-cell type (CLL). PURPOSE-METHODS: To study the clinical significance of functional markers linked to proliferation (CD25), adhesion (CD54), and apoptosis (CD95) on B- and T-cells in 68 patients with CLL using dual colour flow cytometry (FCM).
  
  
  RESULTS
  The mean proportion of CD19+ B-cells expressing CD25 was significantly higher in CLL patients compared to controls (P=0.02), while CD54+ and CD95+ B-cells did not differ significantly. In CLL with atypical morphology and in patients with trisomy 12, the mean percentage of CD25+ B-cells was lower than in typical CLL (P<0.02) and in patients with disomic tumor cells (P<0.03). Patients with 30% of CD25+ B-cells had a shorter median time to treatment than CD25-negative cases (P=0.01). A low CD54 expression was associated with a prolonged median time to treatment (P=0.004), low WBC counts (P<0.05), and low S-LDH (P=0.03). A high CD95 expression was correlated with elevated S-LDH (P=0.02) and a finding of lymphadenopathy (P=0.02). In individual patients there was a strong correlation between B- and T-cell expression of CD25 (P<0.0001), CD54 (P=0.0002), and CD95 (P=0.0002), respectively.
  
  
  CONCLUSIONS
  CD25 and CD54 expression on CD19+ cells seems to give prognostic information. The strong correlation between the expression of CD25, CD54 and CD95 on B-and T-cells suggests that the expression of these antigens is not an inherent characteristic of the malignant B-cell clone.
authors.affiliation: Division of Hematology, Department of Medicine, Karolinska Hospital, Stockholm, Sweden. viktoria.hjalmar@ks.se
authors.forename: Viktoria
authors.initials: V
authors.lastname: Hjalmar
authors.forename: Robert
authors.initials: R
authors.lastname: Hast
authors.forename: Eva
authors.initials: E
authors.lastname: Kimby
mesh_terms: D017209:Apoptosis; D001402:B-Lymphocytes / Q000276:immunology; D002448:Cell Adhesion; D002455:Cell Division; D002881:Chromosomes, Human, Pair 12; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D016130:Immunophenotyping; D017404:In Situ Hybridization, Fluorescence; D018799:Intercellular Adhesion Molecule-1 / Q000032:analysis*; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000235:genetics / Q000276:immunology* / Q000473:pathology; D007958:Leukocyte Count; D008297:Male; D011379:Prognosis; D015375:Receptors, Interleukin-2 / Q000032:analysis*; D013601:T-Lymphocytes / Q000276:immunology; D014314:Trisomy; D019014:fas Receptor / Q000032:analysis*
chemical_list: D015375:Receptors, Interleukin-2; D019014:fas Receptor; D018799:Intercellular Adhesion Molecule-1